AI Article Synopsis
- Researchers have identified rimocidin B (3b) and CE-108B (4b) as new polyene amides with better pharmacological effects, produced by genetically altered Streptomyces diastaticus var. 108.!
- Genetic and biochemical studies indicate that these two amides are modified versions of the original polyenes rimocidin (3a) and CE-108 (4a), involving changes to a specific chemical structure after initial production.!
- Two intermediate polyenes, part of the biosynthetic pathway for rimocidin and CE-108, have also been isolated and shown to possess enhanced pharmacological properties compared to their final forms.
Article Abstract
We recently characterized rimocidin B (3b) and CE-108B (4b) as two polyene amides with improved pharmacological properties, produced by genetically modified Streptomyces diastaticus var. 108. In this work, genetic and biochemical analysis of the producer strain show that the two amides are derived from the parental polyenes rimocidin (3a) and CE-108 (4a) by a post-PKS modification of the free side chain carboxylic acid. This modification is mediated by an amidotransferase activity operating after the biosynthesis of rimocidin (3a) and CE-108 (4a) are completed. Two polyenes, intermediates of the biosynthetic pathway of rimocidin (3a) and CE-108 (4a), were also isolated and shown to have some improved pharmacological properties compared with the final products.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.chembiol.2005.08.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!